Skip to main content
ELAB
NASDAQ Life Sciences

PMGC Subsidiary Secures Second Long-Term Aerospace & Defense Supply Agreement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.16
Mkt Cap
$8.715M
52W Low
$1.62
52W High
$466.2
52W Position info
219% above low
Off High info
99% below high
Rel. Volume info
9.8× avg
Market data snapshot near publication time

ELAB has more than doubled off its 52-week low of $1.62 on elevated volume (9.8× avg).

Summary

PMGC Holdings' subsidiary, AGA Precision Systems, signed its second long-term supply agreement with a major aerospace and defense company, enhancing revenue stability for the financially challenged parent company.


Key Events · M&A and Partnerships · ELAB

  • Second Long-Term Supply Agreement

    AGA Precision Systems, a wholly-owned subsidiary, secured its second long-term agreement in 2026 to supply precision CNC-manufactured components to a globally recognized Tier 1 aerospace and defense company. This formalizes an ongoing multi-year supplier-customer relationship.

  • Strategic Validation

    The agreement demonstrates continued customer confidence in AGA's precision manufacturing capabilities and reinforces its position as a qualified supplier within the U.S. defense supply chain, meeting stringent technical and regulatory requirements.

  • Addresses Going Concern

    This development provides crucial revenue visibility and operational stability for PMGC Holdings, which recently disclosed a going concern warning in its 10-K filing on March 30, 2026, and has been actively seeking capital through dilutive financing.


Analysis · ELAB · Life Sciences

This agreement provides crucial revenue visibility and validates the capabilities of AGA Precision Systems, a wholly-owned subsidiary. For PMGC Holdings, which recently received a going concern warning and has relied on dilutive financing, securing a second long-term contract with a Tier 1 defense firm is a significant positive development that strengthens its operational outlook and potential for recurring revenue. This follows the first long-term agreement announced on March 31, 2026, indicating a positive trend in securing commercial contracts.

At the time of this filing, ELAB was trading at $5.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.62 to $466.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Jul 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.890 info
Change: -$0.140 (-14%) info
Market Cap: $4.089M info
ELAB
Jul 07, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.890 info
Change: -$0.310 (-26%) info
Market Cap: $4.089M info
ELAB
Jul 06, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $0.890 info
Change: -$0.4387 (-33%) info
Market Cap: $4.089M info
ELAB
Jul 01, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $0.890 info
Change: -$0.680 (-43%) info
Market Cap: $4.089M info
ELAB
Jul 01, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.890 info
Change: -$0.390 (-30%) info
Market Cap: $4.089M info